ArticlePharmacoEconomics - open2026
Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain.
Article in PharmacoEconomics - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveChronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated disorder, which causes peripheral nervous system dysfunction. Guidelines recommend maintenance treatment with intravenous (IVIG) or subcutaneous (SCIG) immunoglobulins. Drawbacks for IVIG include the burden of hospital administration, which is less for SCIG, which allows self- or caregiver-assisted administration at home. However, conventional SCIG (c-SCIG) requires more frequent administration than IVIG. Recently, facilitated-SGIG (f-SCIG) was developed, spacing injections so that administration frequency is analogous to IVIG. The aim of this study was to estimate and compare the costs of IVIG, c-SCIG, and f-SCIG for CIDP maintenance treatment in Spain.
methodsA cost-analysis model based on a decision tree was developed to evaluate the annual cost per patient treated with each immunoglobulin from a societal perspective. Costs considered included direct health costs (pharmaceutical acquisition and administration), non-health costs (transport to hospital), and indirect costs related to labor productivity. All costs were valued in 2024 euros.
resultsThe annual cost for a patient with CIDP receiving maintenance treatment was €109,212.67 with IVIG, €98,161.97 with c-SCIG, and €98,191.37 with f-SCIG. Across all treatments, direct healthcare costs were the highest. The main driver of the difference between SCIG and IVIG cost was treatment administration (-€10,705.78). Sensitivity analyses were generally consistent with the base case results.
conclusionsOverall, the findings of this analysis suggest that SCIG may be a cost-saving alternative to IVIG for patients with CIDP requiring maintenance treatment in Spain, with a similar cost between c-SCIG and f-SCIG.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.